Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC

Cho, B. C.Rodriguez-Abreu, D.Hussein, M.Cobo, M.Patel, A.Secen, N.Gerstner, G.Kim, D-W.Lee, Y-G.Su, W-C.Huang, E.Patil, N.Huang, M.Zhang, Z.Wen, X.Mendus, D.Hoang, T.Meng, R.Johnson, M. L.2025-01-072025-01-072021-12-100923-7534https://hdl.handle.net/10668/24517enUpdated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLCconference outputopen access10.1016/j.annonc.2021.10.2171569-8041http://www.annalsofoncology.org/article/S0923753421047736/pdf731051400120